Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Here, we synthesize several lines of evidence supporting the hypothesis that at least one function of amyloid‐β is to serve as a part of the acute response to brain hemodynamic disturbances intended to seal vascular leakage. Given the resilient and adhesive physicochemical properties of amyloid, an abluminal hemostatic repair system might be highly advantageous, if deployed on a limited and short‐term basis, in young individuals. However, in the aged, inevitable cardiovascular dysfunction combined with brain microvascular lesions may yield global chronic hypoperfusion that may lead to continuous amyloid deposition and consequential negative effects on neuronal viability. A large body of experimental evidence supports the hypothesis of an amyloid‐β rescue function gone astray. Preventing or inducing the removal of amyloid in Alzheimer's disease (AD) has been simultaneously successful and disappointing. Amyloid deposits clearly play major roles in AD, but they may not represent the preeminent factor in dementia pathogenesis. Successful application of AD preventative approaches may hinge on an accurate and comprehensive view of comorbidities, including cardiovascular disease, diabetes, and head trauma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“[4] Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al.”
BackgroundO’Rourke, M. F., & Safar, M. E. (2005) · Hypertension · doi:10.1161/01.hyp.0000168052.00426.65 · Cited by 1,279 · cited 2×
“As age advances, there is a direct relationship between stiffening of large elastic arteries and brain microvascular disease [50], as well as with increased pulse pressure and pulse velocity, which are correlated to cognitive decline [53].”
BackgroundThe Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009 · cited 1×
“[79] Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al.”
BackgroundRoher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799 · cited 1×
“[108] Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ,”
BackgroundSelf-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Review: Cerebral microvascular pathology in ageing and neurodegeneration
Brown, W. R., & Thore, C. R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01139.x · Cited by 749
Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., & Ball, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10836 · Cited by 740
Self-citationAlzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680 · cited 3×
“Microhemorrhages are frequently observed in AD patients [97], thus implying that the unchecked accumulation of vascular amyloid can itself be intrinsically destructive.”
BackgroundWeller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y.-M., & Roher, A. E. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65616-7 · Cited by 679
Self-citationThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · cited 1×
“Diabetic patients face a considerably higher risk of developing cardiovascular disease, hypertension, atherosclerosis, and obesity [57,62], as well as brain microvascular changes leading to dysfunctional BBB associated with hypoperfusion and cognitive deficiencies [63–65].”
BackgroundCraft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“Diabetic patients face a considerably higher risk of developing cardiovascular disease, hypertension, atherosclerosis, and obesity [57,62], as well as brain microvascular changes leading to dysfunctional BBB associated with hypoperfusion and cognitive deficiencies [63–65].”
BackgroundWaldstein, S. R., Rice, S. C., Thayer, J. F., Najjar, S. S., Scuteri, A., & Zonderman, A. B. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.093674 · Cited by 462 · cited 2×
“As age advances, there is a direct relationship between stiffening of large elastic arteries and brain microvascular disease [50], as well as with increased pulse pressure and pulse velocity, which are correlated to cognitive decline [53].”
BackgroundAlzheimer's pathology in human temporal cortex surgically excised after severe brain injury
Ikonomovic, M. D., Uryu, K., Abrahamson, E. E., Ciallella, J. R., Trojanowski, J. Q., Lee, V. M.-Y., Clark, R. S., Marion, D. W., Wisniewski, S. R., & DeKosky, S. T. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.06.011 · Cited by 399 · cited 1×
“[72] Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, et al.”
BackgroundInsulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392
Cortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., Bhuvanendran, S., Fenz, K. M., & Strickland, S. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.014 · Cited by 339
The relationship between blood pressure and cognitive function
Novak, V., & Hajjar, I. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.161 · Cited by 299 · cited 1×
“Hypertension is an important risk factor forADbecause of its microangiopathic effects on the brain [21,46] and its relationship to brain microhemorrhages [47].”
BackgroundHouse, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., & Exley, C. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6310 · Cited by 294
Brain Injury After Intracerebral Hemorrhage: The Role of Thrombin and Iron
Hua, Y., Keep, R. F., Hoff, J. T., & Xi, G. (2007) · Stroke · doi:10.1161/01.str.0000247868.97078.10 · Cited by 273
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261 · cited 2×
“[14] Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA.”
BackgroundCardiac Index Is Associated With Brain Aging: The Framingham Heart Study
Jefferson, A. L., Himali, J. J., Beiser, A. S., Au, R., Massaro, J. M., Seshadri, S., Gona, P., Salton, C. J., DeCarli, C., O'Donnell, C. J., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.905091 · Cited by 256
Inhibition of Angiogenesis by Aβ Peptides
Paris, D., Townsend, K., Quadros, A., Humphrey, J., Sun, J., Brem, S., Wotoczek-Obadia, M., DelleDonne, A., Patel, N., Obregon, D. F., et al. (2004) · Angiogenesis · doi:10.1023/b:agen.0000037335.17717.bf · Cited by 148
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
Carlsson, C. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100012 · Cited by 109
Bishop, G. M., & Robinson, S. R. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02303-4 · Cited by 104
Brain Endothelial Cells Synthesize Neurotoxic Thrombin in Alzheimer’s Disease
Yin, X., Wright, J., Wall, T., & Grammas, P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090406 · Cited by 104
Cited by
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Review article What causes alzheimer’s disease?
A. Armstrong, R. (2013) · Folia Neuropathologica · doi:10.5114/fn.2013.37702 · Cited by 217
Neuroinflammation and neurogenesis in Alzheimer's disease and potential therapeutic approaches
Sung, P.-S., Lin, P.-Y., Liu, C.-H., Su, H.-C., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030701 · Cited by 193
“Thus, in AD, the overproduction or accumulation of Aβ could be an attempt to repair the initial neuronal injury and maintain normal brain function [16].”
BackgroundAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
Time to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
Metadata
- Authors
- Kokjohn, T. A., Maarouf, C. L., & Roher, A. E.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-11-03
- Volume
- 8
- Issue
- 6
- Pages
- 574-583
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2139225271
- Cited by
- 30
- References
- 27
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.